Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.

Low to Moderate Load Power Training as an Exercise Intervention for Men With Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy.

The goal of this clinical trial is to learn if a low to moderate load power training program is feasible and effective for improving fitness and quality of life of people with prostate cancer under androgen suppression therapy and bone or lymph node metastasis. The main questions it aims to answer are:

• Does a low to moderate load power training program improve quality of life in people with metastatic prostate cancer under androgen deprivation therapy?
• Does a low to moderate load power training program improve power, strength, endurance, and balance in people with metastatic prostate cancer under androgen deprivation therapy?

Researchers will compare the exercise program with routine care to see if power training works to improve common physical side effects of androgen suppression therapy in patients with metastatic prostate cancer.

Participants will:

• Participate in a supervised exercise program twice a week for 6 months or maintain routine care.
• Perform fitness tests and questionnaires about quality of life and mental health.
• Those who take part in the exercise program will also perform semi-structured in-depth interviews after the end of the program.

Study Overview

• Status: Recruiting
• Conditions: Prostatic Neoplasms
• Intervention / Treatment: Other: Power training group

Detailed Description

Background and Rationale:

Prostate cancer is the most frequently diagnosed cancer among men worldwide, particularly affecting older populations, with increasing incidence and prevalence projected in the coming decades. While survival rates have improved substantially, these advances have not been matched by improvements in long-term quality of life. A significant proportion of patients with advanced prostate cancer undergo androgen deprivation therapy (ADT), which reduces testosterone levels to control tumor progression.

Despite its effectiveness, ADT is associated with multiple adverse effects, including loss of muscle mass and strength, increased adiposity, decreased bone mineral density, chronic fatigue, and metabolic alterations. These changes resemble an accelerated aging process and increase the risk of sarcopenia, osteoporosis, and functional dependency. In addition, ADT has been linked to psychological disturbances, including depression, anxiety, cognitive impairment, and reduced vitality.

Health-related quality of life (HRQoL) is a multidimensional construct encompassing physical, psychological, and social domains. In prostate cancer patients undergoing ADT, quality of life is significantly impaired due to the combined effects of disease burden and treatment-related side effects. Mental health plays a central role in this construct, as cancer diagnosis and treatment are highly stressful experiences that can disrupt identity, autonomy, and life continuity.

Exercise has been identified as an effective non-pharmacological intervention for mitigating many of the adverse effects of ADT. Systematic reviews and meta-analyses have demonstrated that exercise improves muscle strength, cardiorespiratory fitness, functional performance, fatigue, and body composition in this population. Exercise has also been associated with improvements in quality of life and emotional well-being, particularly when interventions are supervised and long-term.

The mechanisms underlying these benefits are multifactorial. Neurobiological processes include increased levels of neurotransmitters and brain-derived neurotrophic factor (BDNF), as well as reduced systemic inflammation. From a psychosocial perspective, exercise enhances self-efficacy, perceived control, and social interaction, all of which contribute to improved mental health.

However, most existing research has focused on aerobic or traditional resistance training protocols aimed at hypertrophy. There is a lack of studies examining power-oriented resistance training, which emphasizes rapid force production at moderate loads. Muscle power declines more rapidly than strength with aging and is a critical determinant of functional independence. It is particularly relevant for activities of daily living such as standing up, climbing stairs, or maintaining balance.

Given that ADT induces an accelerated decline in neuromuscular function, power-oriented training may be especially beneficial in this population. Furthermore, this type of training may use lower loads and avoid excessive fatigue, which may enhance adherence in patients experiencing chronic fatigue.

Additionally, previous studies have relied predominantly on quantitative measures, which may not fully capture the subjective and psychosocial dimensions of exercise participation. A mixed-methods approach is therefore necessary to understand how exercise influences identity, motivation, and psychological adaptation in men with prostate cancer.

Objectives:

Primary Objective

1. To determine the effects of a power-oriented resistance training program on health-related quality of life in older men with metastatic prostate cancer undergoing androgen deprivation therapy.
2. To assess improvements in functional capacity, including strength, balance, and performance in daily activities.

Secondary Objectives

1. To evaluate the effects on mental health outcomes, including anxiety, depression, emotional well-being and self-esteem.
2. To determine the safety and feasibility of power-oriented resistance training.
3. To explore participants' subjective experiences using qualitative methods.

Hypotheses:

1. The intervention will significantly improve quality of life compared to the control group.
2. Power-oriented resistance training will be safe and well tolerated.
3. Functional capacity will significantly improve following the intervention.
4. Participants will show improved mental health outcomes.

5. Qualitative findings will reveal improvements in self-efficacy, identity, and psychosocial adaptation.

   Study Design:

   This study is a randomized controlled trial (RCT) with a mixed-methods approach.

   Participants will be randomly assigned to:

   • Experimental Group: Power-Oriented Resistance Training
   • Control Group: Usual care, with information and guidance on how to be physically active at home.

   The intervention will last 24 weeks, with a 6-month follow-up.

   Participants:

   A total of 66 participants will be recruited, based on power analysis (α = 0.05; power = 0.80; effect size = 0.5). An attrition rate of 20% was also considered.

   Inclusion Criteria:

   • Histopathologically confirmed diagnosis of prostate adenocarcinoma.

     • Metastatic hormone-sensitive prostate cancer (mHSPC), defined as:

   • Presence of metastases at initial diagnosis (synchronous mHSPC), or

   • Development of metastatic disease following prior treatment with curative intent (surgery and/or radiotherapy) (metachronous mHSPC). • Evidence of progression to castration-resistant prostate cancer (CRPC).

     • Ongoing treatment with a doublet regimen consisting of standard androgen deprivation therapy (ADT) in combination with an androgen receptor signaling inhibitor (ARSI), initiated prior to study enrollment.
     • Receipt of bone-protective therapy, including calcium and vitamin D supplementation in combination with bisphosphonates.
     • Presence of metastatic involvement limited to bone and/or lymph nodes.
     • Functionally independent in activities of daily living.

   Exclusion Criteria:

   • Evidence of visceral metastatic disease.
   • Current or prior treatment with a triplet regimen that includes chemotherapy.
   • History of pathological fracture.

   Intervention:

   Power-Oriented Resistance Training

   • Frequency: 2 sessions/week.

   • Intensity: 40-50% 1RM.
   • Execution: High-velocity concentric phase.
   • Volume: Low to moderate.
   • No training to failure. This model is designed to improve functional performance while minimizing fatigue and injury risk.

   Control Group:

   Participants will receive information and guidance for being physically active and perform strength training at home.

   Outcome Measures:

   Primary Outcome • Health-related quality of life (FACT-P).

   Secondary Outcomes

   • Functional capacity: (Rate of force development; Handgrip test; Timed up and go test; 6-Minute Walk Test; 10-meter walking speed; 5 times Sit to stand test).

   • Mental health (anxiety, depression and stress): DASS-21.

   • Self-esteem: Rosenberg scale.

   • Physical activity levels: (IPAQ SF).

   • Adverse events (field diary).

   Qualitative Analysis

   • Semi-structured interviews.

   • Field diaries.

   • Thematic analysis. This will explore identity, motivation, and adaptation processes associated with exercise participation.

   Data Analysis

   • 2 × 2 repeated-measures ANOVA.

   • Effect size calculations.

   • Thematic qualitative analysis.

   Expected Impact.

   This study will:

   • Provide novel evidence on power training in prostate cancer.
   • Inform clinical exercise guidelines.
   • Improve quality of life and mental health.
   • Support integration of exercise into oncology care.

   Conclusion:

   This randomized controlled trial addresses a key gap in exercise oncology by evaluating a power-oriented resistance training program in men undergoing ADT. By combining quantitative and qualitative approaches, the study aims to provide a comprehensive understanding of both physiological and psychosocial outcomes.

• Study Type: Interventional
• Enrollment (Estimated): 66
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Spain
  • Alicante
    • San Vicent del Raspeig, Alicante, Spain, 03690
      • Recruiting
      • University of Alicante
      • Contact: Sergio Sebastia-Amat, PhD; Phone Number: 0034 965903713; Email: sergio.sebastia@ua.es
      • Principal Investigator: SERGIO SEBASTIA-AMAT, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Histopathologically confirmed diagnosis of prostate adenocarcinoma.

  • Metastatic hormone-sensitive prostate cancer (mHSPC), defined as:

• Presence of metastases at initial diagnosis (synchronous mHSPC), or

• Development of metastatic disease following prior treatment with curative intent (surgery and/or radiotherapy) (metachronous mHSPC).

  • Evidence of progression to castration-resistant prostate cancer (CRPC).
  • Ongoing treatment with a doublet regimen consisting of standard androgen deprivation therapy (ADT) in combination with an androgen receptor signaling inhibitor (ARSI), initiated prior to study enrollment.
  • Receipt of bone-protective therapy, including calcium and vitamin D supplementation in combination with bisphosphonates.
  • Presence of metastatic involvement limited to bone and/or lymph nodes.
  • Functionally independent in activities of daily living.

Exclusion Criteria:

• Evidence of visceral metastatic disease.
• Current or prior treatment with a triplet regimen that includes chemotherapy.
• History of pathological fracture.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Power training group; The intervention consists of a supervised power-oriented resistance training program for older men with metastatic prostate cancer undergoing androgen deprivation therapy (ADT). Participants will complete 2 sessions per week over 24 weeks. Training focuses on improving muscle power through exercises performed at moderate intensity (40-50% 1RM), emphasizing a fast concentric phase and controlled eccentric phase. Multi-joint functional exercises targeting major muscle groups are included to enhance strength, balance, and daily functional performance. Training volume is low-to-moderate, and participants do not train to muscular failure, allowing maintenance of movement velocity and reducing fatigue. Adequate rest periods are provided between sets. The program is adapted to the clinical characteristics of the population, minimizing mechanical stress while promoting neuromuscular improvements. It is designed to be safe, feasible, and well-tolerated.	Other: Power training group; The intervention consists of a supervised power-oriented resistance training program for older men with prostate cancer undergoing androgen deprivation therapy (ADT). Participants will complete 2 sessions per week over 24 weeks. Training focuses on improving muscle power through exercises performed at moderate intensity (40-50% 1RM), emphasizing a fast concentric phase and controlled eccentric phase. Multi-joint functional exercises targeting major muscle groups are included to enhance strength, balance, and daily functional performance. Training volume is low-to-moderate, and participants do not train to muscular failure, allowing maintenance of movement velocity and reducing fatigue. Adequate rest periods are provided between sets. The program is adapted to the clinical characteristics of the population, minimizing mechanical stress while promoting neuromuscular improvements. It is designed to be safe, feasible, and well-tolerated, with the aim of improving functional capacity.
No Intervention: Control group; Participants will continue with their usual care and will receive standardized information and guidance on how to remain physically active at home.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Health-related quality of life	Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. This instrument includes the Functional Assessment of Cancer Therapy-General (FACT-G) and a prostate cancer-specific subscale, providing a multidimensional assessment of physical, social/family, emotional, and functional well-being, as well as prostate cancer-related symptoms and concerns. The total score will be used for analysis, with higher scores indicating better quality of life. Results will be expressed in points, with a score range of 0 to 156. In addition, quality of life will be complemented by a final semi-structured interview exploring participants' perceptions and experiences after the intervention.	From enrollment to the end of the exercise program at 6 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of Force Development	A test will be conducted to calculate the rate of force development (RFD), defined as the ability of the neuromuscular system to increase contractile force in an optimal and rapid manner when activating a muscle from a low level or from rest. The assessment will be carried out using Chronojump strain gauges (Boscosystem, Spain) during a knee extension exercise at a 90-degree angle. Force (in Newtons) and time (in milliseconds) will be recorded continuously over a 200 ms time window and combined to report RFD in Newtons per second (N/s), calculated as ΔForce/ΔTime. Three 5-second trials will be performed with a one-minute rest between trials, and the mean of the three trials will be used as the single reported value for statistical analysis.	From enrollment to the end of the exercise program at 6 months.
Lower-body strength	Lower-body strength will be assessed using the Five Times Sit-to-Stand test. Participants will be instructed to stand up and sit down from a chair five times as quickly as possible, with arms crossed over the chest and without using the upper limbs for assistance. Performance will be recorded as the time required to complete the test, expressed in seconds (s).	From enrollment to the end of the exercise program at 6 months.
Handgrip strength	Maximal grip strength will be assessed using a dynamometer (Takei model 5101). Participants will perform two maximal trials with both the dominant and non-dominant hand following the recommendations of the American Society of Hand Therapists). Each contraction will be held for 3 seconds, with a 1-minute rest between trials. The highest value obtained from the two trials will be used for analysis. Results will be expressed in kilogram-force (kgf).	From enrollment to the end of the exercise program at 6 months.
Functional mobility	Functional mobility will be assessed using the Timed Up and Go (TUG) test. Participants will stand up from a chair, walk 3 meters, turn around, walk back, and sit down. One familiarization trial will be allowed before the recorded trial. Performance will be recorded as the time required to complete the test, expressed in seconds (s).	From enrollment to the end of the exercise program at 6 months.
Gait speed	Gait speed will be assessed using the 10-meter walk test. Participants will perform the test at their maximum safe walking speed without running. In accordance with the study protocol, the central 6 meters will be recorded, using dual-beam photocells positioned at meters 2 and 8 to exclude acceleration and deceleration phases. Results will be expressed in meters per second (m/s).	From enrollment to the end of the exercise program at 6 months.
Functional aerobic capacity	Functional exercise capacity will be assessed using the 6-Minute Walk Test. Participants will be instructed to walk as far as possible in 6 minutes along a flat, hard-surfaced standardized course. The total distance covered will be recorded in meters (m).	From enrollment to the end of the exercise program at 6 months.
Static balance	Static balance will be assessed by means of a posturographic analysis using a FreeMed baropodometric platform (Rome, Italy). Static balance will be evaluated under eyes-open and eyes-closed conditions in a random order. Participants will perform three 30-second trials for each condition, with 1 minute of rest between trials. The mean of the three trials will be used for analysis. Stabilometric parameters derived from the center of pressure (CoP) will include total excursion, 95% confidence ellipse area, mean velocity, X-Mean, Y-Mean, X-RMS, and Y-RMS. Results will be expressed using center of pressure-derived stabilometric parameters.	From enrollment to the end of the exercise program at 6 months.
Mental health	Mental health will be assessed using the Depression Anxiety Stress Scales-21 (DASS-21) questionnaire. This self-report instrument evaluates symptoms of depression, anxiety, and stress experienced over the previous week. The total score and domain scores will be used for analysis, with higher scores indicating greater psychological distress. Results will be expressed in points, with a total score range of 0 to 63 and subscale score ranges of 0 to 21 for depression, anxiety, and stress. In addition, mental health will be complemented by a final semi-structured interview exploring participants' perceptions and experiences after the intervention.	From enrollment to the end of the exercise program at 6 months.
Self-esteem	Self-esteem will be assessed using the Rosenberg Self-Esteem Scale (RSES), in its validated Spanish version. This self-report instrument consists of 10 items assessing global self-esteem and self-worth. The total score will be used for analysis, with higher scores indicating higher self-esteem. Results will be expressed in points, with a score range of 10 to 40. In addition, self-esteem will be complemented by a final semi-structured interview exploring participants' perceptions and experiences after the intervention.	From enrollment to the end of the exercise program at 6 months.
Physical activity level	Physical activity level will be assessed using the International Physical Activity Questionnaire-Short Form (IPAQ-SF), in its validated Spanish version. This self-administered questionnaire assesses walking, moderate physical activity, vigorous physical activity, and sedentary time over the previous 7 days. Results will be calculated and expressed in MET-minutes per week (MET-min/week). As this questionnaire is used to estimate physical activity volume, it does not have a fixed minimum or maximum total score.	From enrollment to the end of the exercise program at 6 months.
Body composition	Body composition will be assessed using a Tanita MC-780-P multi-frequency segmental body composition analyzer. This assessment will provide estimates of body weight, body mass index, body fat percentage, fat mass, fat-free mass, and muscle mass. Results will be expressed in the corresponding units for each parameter.	From enrollment to the end of the exercise program at 6 months.

Collaborators and Investigators

• Sponsor: University of Alicante
• Collaborators: Hospital General Universitario Dr. Balmis de Alicante

Publications and helpful links

General Publications

• Aagaard, P., Simonsen, E. B., Andersen, J. L., Magnusson, P., Dyhre-poulsen, P., & Dyhre-Poulsen, P. (2002). Neural adaptation to resistance training: changes in evoked V-wave and H-reflex responses. J Appl Physiol, 92, 2309-2318. https://doi.org/10.1152/japplphysiol.01185
• Bassyouny, N. M., Gouda, M. M., El Din, M. M. E., Sweed, H. S., El Akkad, R. M., Bassyouny, N., & Eldin, M. E. (2024). Impact of Androgen deprivation therapy on cognitive function of elderly men with Prostate Cancer. Cureus, 16(9). doi: 10.7759/cureus.69303
• Bigaran, A., Zopf, E., Gardner, J., La Gerche, A., Murphy, D. G., Howden, E. J., ... & Cormie, P. (2021). The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 24(1), 35-48. https://doi.org/10.1038/s41391-020-00273-5
• Cormie, P., Turner, B., Kaczmarek, E., Drake, D., & Chambers, S. K. (2015). A qualitative exploration of the experience of men with prostate cancer involved in supervised exercise programs. Oncol Nurs Forum, 42(1), 24-32. DOI: 10.1188/15.ONF.24-32
• El Hadouchi, M., de Boer, M., & de Vries, N. M. (2025). The impact of power training on muscle power, physical performance, and functional independence in older adults. Clinical Interventions in Aging, 20, 849-857. https://doi.org/10.2147/CIA.S511954
• Gardner, J. R., Livingston, P. M., & Fraser, S. F. (2014). Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. Journal of Clinical Oncology, 32(4), 335-346. DOI: 10.1200/JCO.2013.49.5523
• Lopez, P., Taaffe, D. R., Newton, R. U., Buffart, L. M., & Galvão, D. A. (2021). What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes. Prostate Cancer and Prostatic Diseases, 24(2), 465-481. https://doi.org/10.1038/s41391-020-00301-4
• Maffiuletti, N. A., Aagaard, P., Blazevich, A. J., Folland, J., Tillin, N., & Duchateau, J. (2016). Rate of force development: physiological and methodological considerations. European Journal of Applied Physiology, 116(6), 1091-1116. https://doi.org/10.1007/s00421-016-3346-6
• Massoeurs, L., Ilie, G., Lawen, T., MacDonald, C., Bradley, C., Vo, J. D. C.-T., & Rutledge, R. D. H. (2021). Psychosocial and functional predictors of mental disorder among prostate cancer survivors: Informing survivorship care programs with evidence-based knowledge. Current Oncology, 28(5), 3918-3931. https://doi.org/10.3390/curroncol28050334
• Rantaniemi, L., Jussila, I., Siltari, A., Ahtiainen, J. P., Hakulinen, A., Harju, E., ... & Murtola, T. J. (2025). Is Exercise During Androgen Deprivation Therapy Effective and Safe? A Randomized Controlled Trial. Scandinavian Journal of Medicine & Science in Sports, 35(6). https://doi.org/10.1111/sms.70084
• Raval, A. D., Chen, S., Littleton, N., Constantinovici, N., & Goebell, P. J. (2025). Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review. BJU International, 135(3), 408-421. https://doi.org/10.1111/bju.16577
• Rodríguez-Rosell, D., Pareja-Blanco, F., Aagaard, P., & González-Badillo, J. J. (2018). Physiological and methodological aspects of rate of force development assessment in human skeletal muscle. Clinical Physiology and Functional Imaging, 38(5), 743-762. https://doi.org/10.1111/cpf.12495
• Shao, W., Zhang, H., Qi, H., & Zhang, Y. (2022). The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: An update systematic review and meta-analysis. PLoS One, 17(2), https://doi.org/10.1371/journal.pone.0263918
• Taaffe, D. R., Newton, R. U., Spry, N., Joseph, D., Chambers, S. K., Gardiner, R. A., Wall, B. A., Cormie, P., Bolam, K. A., & Galvão, D. A. (2017). Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: A year-long randomised controlled trial. European Urology. https://doi.org/10.1016/j.eururo.2017.02.019
• Teleni, L., Chan, R. J., Chan, A., Isenring, E. A., Vela, I., Inder, W. J., & McCarthy, A. L. (2016). Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. Endocrine-related cancer, 23(2), 101-112. https://doi.org/10.1530/ERC-15-0456
• Tian, S., Ding, M., & Sun, H. (2022). The effects of resistance exercise on body composition and physical function in prostate cancer patients undergoing androgen deprivation therapy: an update systematic review and meta-analysis. Aging Male, 25(1), 281-292. https://doi.org/10.1080/13685538.2022.2146670
• Tortosa-Martínez, J., Beltrán-Carrillo, V. J., Romero-Elías, M., Ruiz-Casado, A., Jiménez-Loaisa, A., & González-Cutre, D. (2023). "To be myself again": Perceived benefits of group-based exercise for colorectal cancer patients. European Journal of Oncology Nursing, 66, 102405. https://doi.org/10.1016/j.ejon.2023.102405
• Wilson, R. L., Vulczak, A., Morgans, A. K., Norris, M., Greer, J., Votta, J., ... & Dieli-Conwright, C. M. (2025). Design of debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocol. Frontiers in Sports and Active Living, 7, 1602123. https://doi.org/10.3389/fspor.2025.1602123
• Winters-Stone, K. M., et al. (2014). Skeletal response to resistance and impact training in prostate cancer survivors on androgen deprivation therapy: The POWIR trial. Journal of Bone and Mineral Research, 29(3), 1-9. doi: 10.1249/MSS.0000000000000265
• Winters-Stone KM, Dobek JC, Bennett JA, et al. (2015). Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. Arch Phys Med Rehabil, 96, 7-14. https://doi.org/10.1016/j.apmr.2014.08.010
• Yunfeng, G., Weiyang, H., Xueyang, H., Yilong, H., & Xin, G. (2017). Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: an update meta-analysis. Medicine, 96(27), e7368. DOI: 10.1097/MD.0000000000007368
• Ziaee, S., Chu, G. C. Y., Huang, J. M., Sieh, S., & Chung, L. W. K. (2015). Prostate cancer metastasis: Roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics. In Translational Andrology and Urology, 4(4), 438-454. https://doi.org/10.3978/j.issn.2223-4683.2015.04.10

Helpful Links

• Ethics Committee approval document

Study record dates

Study Major Dates

• Study Start (Actual): April 10, 2024
• Primary Completion (Estimated): November 10, 2026
• Study Completion (Estimated): December 10, 2026

Study Registration Dates

• First Submitted: March 31, 2026
• First Submitted That Met QC Criteria: April 30, 2026
• First Posted (Actual): May 7, 2026

Study Record Updates

• Last Update Posted (Actual): May 7, 2026
• Last Update Submitted That Met QC Criteria: April 30, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Exercise; Quality of life; Metastatic prostate cancer; Prostate cancer; Mental health; Movement; Motor Activity; Neoplasm; Testosterone; Power training; Strength training; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Metastasis; Functional capacity; Musculoskeletal and Neural Physiological Phenomena; Androgen; Prostatic; Genital Diseases; Androgen deprivation; Musculoskeletal Physiological Phenomena; Deprivation; Urogenital Diseases
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Site; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Neoplastic Processes; Pathological Conditions, Signs and Symptoms; Behavior; Personal Satisfaction; Urogenital Diseases; Genital Diseases; Neoplasms; Prostatic Neoplasms; Neoplasm Metastasis; Urogenital Neoplasms; Genital Neoplasms, Male; Psychological Well-Being; Motor Activity
• Other Study ID Numbers: UA-2024-01- 23_2

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Data sharing plans have not yet been determined. Decisions regarding the sharing of individual participant data will be made in accordance with ethical considerations, data protection regulations, and institutional policies.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No